Literature DB >> 21356273

The ghrelin axis in disease: potential therapeutic indications.

Ralf Nass1, Bruce D Gaylinn, Michael O Thorner.   

Abstract

Ghrelin, the natural ligand for the growth hormone (GH)-secretagogue receptor (GHS-R), is produced predominantly in the stomach. It is present in the circulation in two major forms, an acylated and an unacylated form, both of which have reported activities. Some of the best understood actions of acylated ghrelin administration are its orexigenic effects, and the stimulation of GH secretion. Ghrelin also seems to play a role in glucose homeostasis, lipid metabolism and immune function. Based on its orexigenic and metabolic effects, ghrelin and ghrelin mimetics have potential benefit in antagonizing protein breakdown and weight loss in catabolic conditions such as cancer cachexia, renal, cardiac and pulmonary disease, and age-related frailty. Ghrelin also has potentially useful positive effects on cardiac function and gastric motility. Ghrelin antagonists may be of benefit to increase insulin sensitivity and potentiate weight loss. The following chapter presents some background on ghrelin and ghrelin assays and discusses some of the potential therapeutic approaches for the use of ghrelin, ghrelin mimetic compounds and ghrelin antagonists in clinical disease.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21356273      PMCID: PMC3114265          DOI: 10.1016/j.mce.2011.02.010

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  58 in total

1.  Ghrelin and cortistatin in lung cancer: expression of peptides and related receptors in human primary tumors and in vitro effect on the H345 small cell carcinoma cell line.

Authors:  P Cassoni; E Allia; T Marrocco; C Ghè; E Ghigo; G Muccioli; M Papotti
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

2.  Simultaneous quantification of ghrelin and desacyl-ghrelin by liquid chromatography-tandem mass spectrometry in plasma, serum, and cell supernatants.

Authors:  Manfred Rauh; Michael Gröschl; Wolfgang Rascher
Journal:  Clin Chem       Date:  2007-03-23       Impact factor: 8.327

3.  Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss.

Authors:  William P Esler; Joachim Rudolph; Thomas H Claus; Weifeng Tang; Nicole Barucci; Su-Ellen Brown; William Bullock; Michelle Daly; Lynn Decarr; Yaxin Li; Lucinda Milardo; David Molstad; Jian Zhu; Stephen J Gardell; James N Livingston; Laurel J Sweet
Journal:  Endocrinology       Date:  2007-07-26       Impact factor: 4.736

4.  Effects of ghrelin on anorexia in tumor-bearing mice with eicosanoid-related cachexia.

Authors:  Wenhua Wang; Marianne Andersson; Britt-Marie Iresjö; Christina Lönnroth; Kent Lundholm
Journal:  Int J Oncol       Date:  2006-06       Impact factor: 5.650

5.  Ghrelin stimulates gastric emptying and hunger in normal-weight humans.

Authors:  F Levin; T Edholm; P T Schmidt; P Grybäck; H Jacobsson; M Degerblad; C Höybye; J J Holst; J F Rehfeld; P M Hellström; E Näslund
Journal:  J Clin Endocrinol Metab       Date:  2006-06-13       Impact factor: 5.958

6.  Influence of ghrelin on interdigestive gastrointestinal motility in humans.

Authors:  J Tack; I Depoortere; R Bisschops; C Delporte; B Coulie; A Meulemans; J Janssens; T Peeters
Journal:  Gut       Date:  2005-10-10       Impact factor: 23.059

7.  Ghrelin stimulates growth hormone secretion and food intake in aged rats.

Authors:  Koji Toshinai; Muhtashan S Mondal; Takuya Shimbara; Hideki Yamaguchi; Yukari Date; Kenji Kangawa; Masamitsu Nakazato
Journal:  Mech Ageing Dev       Date:  2006-11-15       Impact factor: 5.432

8.  Ghrelin and growth hormone secretagogue receptor expression in mice during aging.

Authors:  Yuxiang Sun; Jose Manuel Garcia; Roy G Smith
Journal:  Endocrinology       Date:  2006-12-07       Impact factor: 4.736

9.  Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans.

Authors:  Jenny Tong; Ronald L Prigeon; Harold W Davis; Martin Bidlingmaier; Steven E Kahn; David E Cummings; Matthias H Tschöp; David D'Alessio
Journal:  Diabetes       Date:  2010-06-28       Impact factor: 9.461

10.  Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia.

Authors:  Mark D DeBoer; Xin Xia Zhu; Peter Levasseur; Michael M Meguid; Susumu Suzuki; Akio Inui; John E Taylor; Heather A Halem; Jesse Z Dong; Rakesh Datta; Michael D Culler; Daniel L Marks
Journal:  Endocrinology       Date:  2007-03-08       Impact factor: 4.736

View more
  10 in total

Review 1.  The GH/IGF-1 system in critical illness.

Authors:  Itoro E Elijah; Ludwik K Branski; Celeste C Finnerty; David N Herndon
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2011-10       Impact factor: 4.690

2.  Hypotensive effects of ghrelin receptor agonists mediated through a novel receptor.

Authors:  Brid Callaghan; Samin Kosari; Ruslan V Pustovit; Daniela M Sartor; Dorota Ferens; Kung Ban; Jonathan Baell; Trung V Nguyen; Leni R Rivera; James A Brock; John B Furness
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

Review 3.  Recent advances in pharmacological, hormonal, and nutritional intervention for sarcopenia.

Authors:  Kunihiro Sakuma; Akihiko Yamaguchi
Journal:  Pflugers Arch       Date:  2017-10-18       Impact factor: 3.657

Review 4.  Ghrelin and Cancer: Examining the Roles of the Ghrelin Axis in Tumor Growth and Progression.

Authors:  Anuhya S Kotta; Abigail S Kelling; Karen A Corleto; Yuxiang Sun; Erin D Giles
Journal:  Biomolecules       Date:  2022-03-22

5.  Age-dependent decline in acyl-ghrelin concentrations and reduced association of acyl-ghrelin and growth hormone in healthy older adults.

Authors:  Ralf Nass; Leon S Farhy; Jianhua Liu; Suzan S Pezzoli; Michael L Johnson; Bruce D Gaylinn; Michael O Thorner
Journal:  J Clin Endocrinol Metab       Date:  2013-11-27       Impact factor: 5.958

6.  Deletion of G-protein-coupled receptor 55 promotes obesity by reducing physical activity.

Authors:  A Meadows; J H Lee; C-S Wu; Q Wei; G Pradhan; M Yafi; H-C Lu; Y Sun
Journal:  Int J Obes (Lond)       Date:  2015-10-08       Impact factor: 5.095

7.  Induced ablation of ghrelin cells in adult mice does not decrease food intake, body weight, or response to high-fat diet.

Authors:  Matthew R McFarlane; Michael S Brown; Joseph L Goldstein; Tong-Jin Zhao
Journal:  Cell Metab       Date:  2014-05-15       Impact factor: 27.287

8.  Upper gastrointestinal dysmotility after spinal cord injury: is diminished vagal sensory processing one culprit?

Authors:  Gregory M Holmes
Journal:  Front Physiol       Date:  2012-07-17       Impact factor: 4.566

Review 9.  From Belly to Brain: Targeting the Ghrelin Receptor in Appetite and Food Intake Regulation.

Authors:  Ken Howick; Brendan T Griffin; John F Cryan; Harriët Schellekens
Journal:  Int J Mol Sci       Date:  2017-01-27       Impact factor: 5.923

10.  Ghrelin is a prognostic marker and a potential therapeutic target in breast cancer.

Authors:  Malin Grönberg; Cecilia Ahlin; Ylva Naeser; Eva Tiensuu Janson; Lars Holmberg; Marie-Louise Fjällskog
Journal:  PLoS One       Date:  2017-04-18       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.